Evidence map›Paper›PMID 27252424›Full record

ArticleThe Journal of rheumatology2016

Visual Complications in Patients with Biopsy-proven Giant Cell Arteritis: A Population-based Study.

Muna Saleh, Carl Turesson, Martin Englund, Peter A Merkel, Aladdin J Mohammad

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Giant cell arteritis: Its ophthalmic manifestations.Indian journal of ophthalmology · 2021
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Muna SalehFrom the Department of Internal Medicine, Section of Rheumatology, Helsingborg Hospital, Helsingborg; Lund University, Skåne University Hospital, Department of Clinical Sciences Malmö, Rheumatology, Malmö; Department of Clinical Sciences, Orthopaedics and Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK.M. Saleh, MD, Department of Internal Medicine, Section of Rheumatology, Helsingborg Hospital; C. Turesson, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Malmö, Rheumatology, Malmö; M. Englund, MD, PhD, Department of Clinical Sciences, Orthopaedics, Lund University, and the Clinical Epidemiology Research and Training Unit, Boston University School of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology, University of Pennsylvania; A.J. Mohammad, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, and the Vasculitis and Lupus Clinic, Addenbrooke's Hospital.
Carl TuressonFrom the Department of Internal Medicine, Section of Rheumatology, Helsingborg Hospital, Helsingborg; Lund University, Skåne University Hospital, Department of Clinical Sciences Malmö, Rheumatology, Malmö; Department of Clinical Sciences, Orthopaedics and Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK.M. Saleh, MD, Department of Internal Medicine, Section of Rheumatology, Helsingborg Hospital; C. Turesson, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Malmö, Rheumatology, Malmö; M. Englund, MD, PhD, Department of Clinical Sciences, Orthopaedics, Lund University, and the Clinical Epidemiology Research and Training Unit, Boston University School of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology, University of Pennsylvania; A.J. Mohammad, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, and the Vasculitis and Lupus Clinic, Addenbrooke's Hospital.
Martin EnglundFrom the Department of Internal Medicine, Section of Rheumatology, Helsingborg Hospital, Helsingborg; Lund University, Skåne University Hospital, Department of Clinical Sciences Malmö, Rheumatology, Malmö; Department of Clinical Sciences, Orthopaedics and Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK.M. Saleh, MD, Department of Internal Medicine, Section of Rheumatology, Helsingborg Hospital; C. Turesson, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Malmö, Rheumatology, Malmö; M. Englund, MD, PhD, Department of Clinical Sciences, Orthopaedics, Lund University, and the Clinical Epidemiology Research and Training Unit, Boston University School of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology, University of Pennsylvania; A.J. Mohammad, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, and the Vasculitis and Lupus Clinic, Addenbrooke's Hospital.
Peter A MerkelFrom the Department of Internal Medicine, Section of Rheumatology, Helsingborg Hospital, Helsingborg; Lund University, Skåne University Hospital, Department of Clinical Sciences Malmö, Rheumatology, Malmö; Department of Clinical Sciences, Orthopaedics and Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK.M. Saleh, MD, Department of Internal Medicine, Section of Rheumatology, Helsingborg Hospital; C. Turesson, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Malmö, Rheumatology, Malmö; M. Englund, MD, PhD, Department of Clinical Sciences, Orthopaedics, Lund University, and the Clinical Epidemiology Research and Training Unit, Boston University School of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology, University of Pennsylvania; A.J. Mohammad, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, and the Vasculitis and Lupus Clinic, Addenbrooke's Hospital.
Aladdin J MohammadFrom the Department of Internal Medicine, Section of Rheumatology, Helsingborg Hospital, Helsingborg; Lund University, Skåne University Hospital, Department of Clinical Sciences Malmö, Rheumatology, Malmö; Department of Clinical Sciences, Orthopaedics and Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, Massachusetts; Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK.M. Saleh, MD, Department of Internal Medicine, Section of Rheumatology, Helsingborg Hospital; C. Turesson, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Malmö, Rheumatology, Malmö; M. Englund, MD, PhD, Department of Clinical Sciences, Orthopaedics, Lund University, and the Clinical Epidemiology Research and Training Unit, Boston University School of Medicine; P.A. Merkel, MD, MPH, Division of Rheumatology, University of Pennsylvania; A.J. Mohammad, MD, PhD, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, and the Vasculitis and Lupus Clinic, Addenbrooke's Hospital. Aladdin.mohammad@med.lu.se.

Funding

VASCULITIS CLINICAL RESEARCH NETWORK (VCRN): RARE DISEASEU54RR019497 · NCRR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MERKEL, PETER A · 2003 to 2008
$6.1M
NCRR NIH HHS U54 RR019497
6 · The paper itself

Abstract

objectiveTo study the clinical and laboratory characteristics of patients with biopsy-proven giant cell arteritis (GCA) with visual complications, and to evaluate the incidence rate of visual complications in GCA compared to the background population.

methodsData from 840 patients with GCA in the county of Skåne, Sweden, diagnosed between 1997 and 2010, were used for this analysis. Cases with visual complications were identified from a diagnosis registry and confirmed by a review of medical records. The rate of visual complications in patients with GCA was compared with an age- and sex-matched reference population.

resultsThere were 85 patients (10%) who developed ≥ 1 visual complication after the onset of GCA. Of the patients, 18 (21%) developed unilateral or bilateral complete visual loss. The mean age at diagnosis was 78 years (± 7.3); 69% were women. Compared with patients without visual complications, those with visual complication had lower C-reactive protein levels at diagnosis and were less likely to have headache, fever, and palpable abnormal temporal artery. The use of β-adrenergic inhibitors was associated with visual complications. The incidence of visual complications among patients with GCA was 20.9/1000 person-years of followup compared to 6.9/1000 person-years in the reference population, resulting in a rate ratio of 3.0 (95% CI 2.3-3.8).

conclusionTen percent of patients with GCA developed visual complications, a rate substantially higher than that of the general population. Patients with GCA who had visual complications had lower inflammatory responses and were more likely to have been treated with β-adrenergic inhibitors compared with patients without visual complications.

Indexed as

AgedAged, 80 and overBiopsyC-Reactive ProteinFemaleGiant Cell ArteritisHumansIncidenceMaleRetrospective StudiesRisk FactorsSwedenVision DisordersC-Reactive ProteinCLINICAL CHARACTERISTICSGIANT CELL ARTERITISINFLAMMATIONRATE RATIOVISUAL COMPLICATIONSβ-BLOCKERS

Identifiers

PMID27252424
PMCPMC7350139

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.